Lymphoma - Pipeline Review, H2 2012

Lymphoma - Pipeline Review, H2 2012

Aug 2012 Global Markets Direct Lymphoma554 Pages Price :
$ 2500

Lymphoma Pipeline Review, H2 2012

Global Markets Directs, \'Lymphoma Pipeline Review, H2 2012\', provides an overview of the Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphoma. \'Lymphoma Pipeline Review, H2 2012\' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Lymphoma.
  • A review of the Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Lymphoma pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Lymphoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Lymphoma pipeline depth and focus of Lymphoma therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Lymphoma Therapeutic Products under Development, Key Players in Lymphoma Therapeutics, Lymphoma Pipeline Overview, Lymphoma Pipeline, Lymphoma Pipeline Assessment
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 16
Introduction 17
Global Markets Direct Report Coverage 17
Lymphoma Overview 18
Therapeutics Development 19
An Overview of Pipeline Products for Lymphoma 19
Lymphoma Therapeutics under Development by Companies 21
Lymphoma Therapeutics under Investigation by Universities/Institutes 32
Late Stage Products 49
Comparative Analysis 49
Mid Clinical Stage Products 50
Comparative Analysis 50
Early Clinical Stage Products 51
Comparative Analysis 51
Discovery and Pre-Clinical Stage Products 52
Comparative Analysis 52
Lymphoma Therapeutics Products under Development by Companies 53
Lymphoma Therapeutics Products under Investigation by Universities/Institutes 69
Companies Involved in Lymphoma Therapeutics Development 123
Bristol-Myers Squibb Company 123
Johnson & Johnson 124
F. Hoffmann-La Roche Ltd. 125
Kyowa Hakko Kirin Co., Ltd. 126
Abbott Laboratories 127
Amgen Inc. 128
Sanofi-Aventis 129
AstraZeneca PLC 130
Eli Lilly and Company 131
GlaxoSmithKline plc 132
Seattle Genetics, Inc. 133
Tekmira Pharmaceuticals Corp. 134
Genentech, Inc. 135
Antigenics, Inc. 136
MMR Information Systems, Inc. 137
MedImmune LLC 138
Gilead Sciences, Inc. 139
Daiichi Sankyo Company, Ltd 140
Merck & Co., Inc. 141
Emergent BioSolutions Inc. 142
Lentigen Corporation 143
Gamida Cell Ltd. 144
Takeda Pharmaceutical Company Limited 145
Reliance Life Sciences Pvt. Ltd. 146
Piramal Healthcare Limited 147
Celltrion, Inc. 148
Bio-Path Holdings, Inc. 149
ZIOPHARM Oncology, Inc. 150
Millennium Pharmaceuticals, Inc. 151
Novartis AG 152
Astellas Pharma Inc. 153
Biocon Limited 154
BioMarin Pharmaceutical Inc. 155
Cephalon, Inc. 156
Chong Kun Dang Pharmaceutical 157
Eisai Co., Ltd. 158
Glenmark Pharmaceuticals Ltd. 159
OSI Pharmaceuticals, Inc. 160
Pfizer Inc. 161
SuperGen, Inc. 162
Teva Pharmaceutical Industries Limited 163
Cell Therapeutics, Inc. 164
Genmab A/S 165
Santaris Pharma A/S 166
Alfacell Corporation 167
Celgene Corporation 168
Onyx Pharmaceuticals, Inc. 169
Bayer AG 170
Incyte Corporation 171
Merck KGaA 172
Access Pharmaceuticals, Inc. 173
4SC AG 174
EpiCept Corporation 175
Celldex Therapeutics, Inc. 176
AEterna Zentaris Inc. 177
IMMUNOMEDICS, INC 178
Idera Pharmaceuticals, Inc. 179
MethylGene Inc 180
Northwest Biotherapeutics, Inc. 181
Cleveland BioLabs, Inc. 182
Curis, Inc. 183
Accentia Biopharmaceuticals, Inc. 184
Allos Therapeutics, Inc 185
Portola Pharmaceuticals, Inc. 186
Telik, Inc. 187
TopoTarget A/S 188
Mundipharma International Limited 189
Pharmacyclics, Inc. 190
Senesco Technologies, Inc. 191
Progen Pharmaceuticals Limited 192
Green Cross Corporation 193
SymBio Pharmaceuticals Limited 194
Debiopharm Group 195
Chroma Therapeutics Ltd. 196
Chipscreen Biosciences Ltd 197
Memgen, LLC. 198
Aquinox Pharmaceuticals Inc. 199
Aegera Therapeutics Inc. 200
Ascenta Therapeutics, Inc. 201
Cerulean Pharma, Inc. 202
Provenance Biopharmaceuticals Corp. 203
Arno Therapeutics, Inc. 204
TetraLogic Pharmaceuticals 205
Celentyx Ltd. 206
Fresenius Biotech GmbH 207
Semafore Pharmaceuticals, Inc. 208
MSM Protein Technologies, Inc. 209
Jennerex Biotherapeutics, Inc. 210
Synageva BioPharma Corp. 211
Cornerstone Pharmaceuticals, Inc. 212
Omnitura Therapeutics Inc. 213
Yaupon Therapeutics, Inc. 214
Onconova Therapeutics, Inc 215
TcL Pharma SAS 216
Immune System Therapeutics Ltd. 217
Intellikine, Inc. 218
Myriad Pharmaceuticals, Inc. 219
Morphogenesis, Inc. 220
Mirna Therapeutics, Inc. 221
Transtech Pharma, Inc. 222
Xencor, Inc. 223
iBio, Inc. 224
Synthon Pharmaceuticals, Inc. 225
PharmaMar, S.A. 226
VentiRx Pharmaceuticals, Inc. 227
Kinex Pharmaceuticals, LLC 228
CureTech Ltd. 229
Cylene Pharmaceuticals, Inc. 230
Nereus Pharmaceuticals, Inc. 231
AVEO Pharmaceuticals, Inc. 232
Lytix Biopharma AS 233
KAHR medical Ltd. 234
Astellas Pharma GmbH 235
Dynamix Pharmaceuticals Ltd. 236
Cancer Therapeutics CRC Pty Ltd 237
Zenyaku Kogyo Co., Ltd. 238
LFB Biotechnologies, S.A.S.U. 239
Mebiopharm Co., Ltd. 240
Polaris Group 241
Probiomed S.A. de C.V. 242
ImQuest Life Sciences 243
Shanghai CP Guojian Pharmaceutical Co.,Ltd. 244
Immunovative Therapies, Ltd. 245
PharmaTech International, Inc. 246
Cell>Point 247
Advancell 248
Lymphoma Therapeutics Assessment 249
Assessment by Monotherapy Products 249
Assessment by Combination Products 250
Assessment by Route of Administration 251
Assessment by Molecule Type 253
Drug Profiles 256
StemEx - Drug Profile 256
obinutuzumab - Drug Profile 258
Enzastaurin - Drug Profile 259
MAbThera - Drug Profile 261
MLN8237 - Drug Profile 263
BiovaxID - Drug Profile 265
Chidamide - Drug Profile 267
Velcade - Drug Profile 268
Afinitor - Drug Profile 269
Bendamustine Hydrochloride - Drug Profile 272
Mechlorethamine Gel - Drug Profile 274
Folotyn - Drug Profile 275
Rituximab - Drug Profile 278
Rituximab + Fludarabine + Cyclophosphamide - Drug Profile 279
Cyclophosphamide + Total Body Radiation - Drug Profile 281
Fludarabine + Melphalan + Allogeneic Stem Cell Transplantation - Drug Profile 282
Cyclophosphamide + Etoposide + Total Body Irradiation - Drug Profile 283
Carboplatin + Thiotepa + Cyclophosphamide + Allogeneic Stem Cell Transplantation - Drug Profile 284
CHOP-14 + Alemtuzumab - Drug Profile 285
Anti-Thymocyte Globulin + Cyclophosphamide + Allogeneic Stem Cell Transplantation - Drug Profile 287
Bendamustine + Rituximab - Drug Profile 289
Fludarabine Phosphate - Drug Profile 290
Cyclophosphamide + Epirubicin + Vincristine + Prednisone - Drug Profile 291
Rituximab + Chlorambucil - Drug Profile 293
Rituximab - Drug Profile 294
Chlorambucil - Drug Profile 295
Mitoxantrone + Chlorambucil + Dexamethasone - Drug Profile 296
Mitoxantrone + Dexamethasone + Fludarabine - Drug Profile 298
Fludarabine Phosphate - Drug Profile 300
Ondansetron - Drug Profile 301
Levofloxacin - Drug Profile 302
Treanda + Rituxan - Drug Profile 303
Revlimid - Drug Profile 305
Arzerra + Bendamustine - Drug Profile 307
Arzerra + DHAP + Stem Cell Transplant - Drug Profile 309
Pixantrone + Rituximab - Drug Profile 312
Avastin + R-CHOP - Drug Profile 313
RG7159 + CHOP - Drug Profile 315
Fludarabine + Mitoxantrone + Dexamethasone + Rituximab - Drug Profile 318
Filgrastim + Rituximab + Carboplatin + Etoposide + Ifosfamide - Drug Profile 320
Filgrastim + Rituximab + Carboplatin + Etoposide + Ifosfamide - Drug Profile 322
AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine - Drug Profile 324
Fludarabine + Total Body Irradiation + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 326
CHOP14 + G-CSF + MabCampath + Autologous Stem Cell Transplantation - Drug Profile 328
EPOCH + Rituximab - Drug Profile 330
Rituximab - Drug Profile 332
Asparaginase + Cyclophosphamide + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Mercaptopurine + Methotrexate + Methylprednisolone + Mitoxantrone Hydrochloride + Prednisone + Vincristine Sulfate + Radiation Therapy - Drug Profile 334
Rituximab - Drug Profile 337
Rituximab + Cyclophosphamide + Vincristine + Prednisone + Doxorubicin - Drug Profile 339
Rituximab + Cyclophosphamide + Hydroxydaunorubicin Hydrochloride + Oncovin + Prednisone - Drug Profile 341
Rituximab + Cyclophosphamide + Hydroxydaunorubicin Hydrochloride + Oncovin + Prednisone + Darbepoetin Alpha - Drug Profile 343
VELCADE-R-CAP - Drug Profile 345
Arzerra - Drug Profile 347
Cyclophosphamide + Vincristine + Prednisolone + Mabthera + Radiotherapy - Drug Profile 351
Rituximab + Cyclophosphamide + Fludarabine - Drug Profile 353
Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Cisplatin + Dexamethasone + Cytarabine + Melphalan + Radiation Therapy + Stem Cell Transplantation - Drug Profile 354
R-CHOP + Radiation Therapy - Drug Profile 356
Bexxar + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 358
Cyclophosphamide + Total-Body Irradiation + Autologous Stem Cell Transplantation - Drug Profile 360
Busulfan + Cyclophosphamide + Autologous Stem Cell Transplantation - Drug Profile 361
Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine - Drug Profile 362
Cyclophosphamide + Doxorubicin + Prednisone + Vincristine + Iodine-131 Tositumomab - Drug Profile 364
FavId + Sargramostim + Rituximab - Drug Profile 366
Rituximab + Doxorubicin + Vincristine + Prednisone - Drug Profile 368
Cyclophosphamide + Hydroxydaunorubicin + Vincristine + Prednisone + G-CSF + Alemtuzumab - Drug Profile 370
Fludarabine + Novantrone + Decadron + Rituximab + Interferon - Drug Profile 372
Rituximab + Fludarabine + Cyclophosphamide - Drug Profile 374
Carmustine + Cyclophosphamide + Cytarabine + Etoposide + Melphalan + Autologous Stem Cell Transplantation + Rituximab - Drug Profile 376
R-CHOP14 + Neulasta - Drug Profile 378
Procrit - Drug Profile 380
Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone - Drug Profile 381
Umbilical Cord Blood Transplantation - Drug Profile 383
AME-133v - Drug Profile 385
DHAP + Rituximab - Drug Profile 386
ICE + RITUXIMAB - Drug Profile 387
bone marrow transplantation + T cell-depleted bone marrow transplantation - Drug Profile 388
bone marrow transplantation + T cell-depleted bone marrow transplantation - Drug Profile 389
Filgrastim + Rituximab + Sargramostim + CHOP Regimen + Carmustine + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Prednisone + Vincristine + Stem Cell Transplantation + Radiation Therapy - Drug Profile 390
Filgrastim + Rituximab + Sargramostim + CHOP Regimen + Carmustine + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Prednisone + Vincristine + Stem Cell Transplantation + Radiation Therapy - Drug Profile 393
Bleomycin + Recombinant Interferon Alfa + Cisplatin + Cyclophosphamide + Idarubicin + Leucovorin + Methotrexate + Methylprednisolone + Vincristine + Peripheral Blood Stem Cell Transplantation + Radiation Therapy - Drug Profile 396
Mitoxantrone Hydrochloride + Chlorambucil + Dexamethasone - Drug Profile 399
Cyclosporine + Methotrexate + T Cell Depletion - Drug Profile 401
Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Rituximab + G-CSF - Drug Profile 403
Cyclophosphamide + Vincristine + Prednisone + Epirubicin + Rituximab + G-CSF - Drug Profile 405
Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Rituximab + G-CSF - Drug Profile 408
R-FM - Drug Profile 411
R-CVP - Drug Profile 412
Cyclophosphamide + Prednisone + Epirubicin + Vinblastine + Rituximab + G-CSF - Drug Profile 414
Dactinomycin + Sargramostim + CHOP Regimen + Carmustine + Cytarabine + Daunorubicin Hydrochloride + Etoposide + Mercaptopurine + Methotrexate + Mitoxantrone Hydrochloride + Pegaspargase + Prednisone + Vincristine - Drug Profile 416
R-CHOP14 + Darbepoetin Alfa - Drug Profile 420
Rituximab-HDS - Drug Profile 422
Cyclophosphamide + Radiation Therapy + Allogeneic Stem Cell Transplantation - Drug Profile 423
Bleomycin Sulfate + CHOP Regimen + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Mitoxantrone Hydrochloride + Prednisolone + Vincristine Sulfate - Drug Profile 425
Bleomycin Sulfate + Rituximab + CHOP Regimen + EPOCH Regimen + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Methotrexate + Mitoxantrone Hydrochloride + Prednisolone + Prednisone + Vincristine Sulfate - Drug Profile 428
Cyclosporine + Methotrexate + Cyclosporine + T Cell Depletion - Drug Profile 432
Filgrastim + Recombinant Interferon Alfa + Carmustine + Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Melphalan + Radiation Therapy + Peripheral Blood Stem Cell Transplantation - Drug Profile 434
Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine + Filgrastim + Carboplatin + Etoposide + Ifosfamide - Drug Profile 437
Cyclophosphamide + Cyclosporine + Methotrexate + G-CSF + Radiation Therapy - Drug Profile 440
Fludarabine Phosphate + Mitoxantrone Hydrochloride + Dexamethasone - Drug Profile 442
Lenalidomide - Drug Profile 444
R-CHOP - Drug Profile 445
Revlimid + Rituxan - Drug Profile 447
GP2013 - Drug Profile 448
Bortezomib + Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisolone - Drug Profile 449
CMAB304 + CHOP - Drug Profile 451
Rituximab Biosimilar + CHOP - Drug Profile 453
Lymphoma Therapeutics Drug Profile Updates 455
Lymphoma Therapeutics Discontinued Products 481
Lymphoma Therapeutics - Dormant Products 493
Lymphoma Product Development Milestones 538
Featured News & Press Releases 538

Appendix 546
Methodology 546
Coverage 546
Secondary Research 546
Primary Research 546
Expert Panel Validation 546
Contact Us 547
Disclaimer 547

List of Table


Number of Products Under Development for Lymphoma, H2 2012 26
Products under Development for Lymphoma Comparative Analysis, H2 2012 27
Number of Products under Development by Companies, H2 2012 29
Number of Products under Development by Companies, H2 2012 (Contd..1) 30
Number of Products under Development by Companies, H2 2012 (Contd..2) 31
Number of Products under Development by Companies, H2 2012 (Contd..3) 32
Number of Products under Development by Companies, H2 2012 (Contd..4) 33
Number of Products under Development by Companies, H2 2012 (Contd..5) 34
Number of Products under Development by Companies, H2 2012 (Contd..6) 35
Number of Products under Development by Companies, H2 2012 (Contd..7) 36
Number of Products under Development by Companies, H2 2012 (Contd..8) 37
Number of Products under Development by Companies, H2 2012 (Contd..9) 38
Number of Products under Investigation by Universities/Institutes, H2 2012 40
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 41
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 42
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 43
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 45
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 46
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 47
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 48
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 49
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 50
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 51
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 52
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 53
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 54
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 55
Comparative Analysis by Late Stage Development, H2 2012 56
Comparative Analysis by Mid Clinical Stage Development, H2 2012 57
Comparative Analysis by Early Clinical Stage Development, H2 2012 58
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 59
Products under Development by Companies, H2 2012 60
Products under Development by Companies, H2 2012 (Contd..1) 61
Products under Development by Companies, H2 2012 (Contd..2) 62
Products under Development by Companies, H2 2012 (Contd..3) 63
Products under Development by Companies, H2 2012 (Contd..4) 64
Products under Development by Companies, H2 2012 (Contd..5) 65
Products under Development by Companies, H2 2012 (Contd..6) 66
Products under Development by Companies, H2 2012 (Contd..7) 67
Products under Development by Companies, H2 2012 (Contd..8) 68
Products under Development by Companies, H2 2012 (Contd..9) 69
Products under Development by Companies, H2 2012 (Contd..10) 70
Products under Development by Companies, H2 2012 (Contd..11) 71
Products under Development by Companies, H2 2012 (Contd..12) 72
Products under Development by Companies, H2 2012 (Contd..13) 73
Products under Development by Companies, H2 2012 (Contd..14) 74
Products under Development by Companies, H2 2012 (Contd..15) 75
Products under Investigation by Universities/Institutes, H2 2012 76
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 77
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 78
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 79
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 80
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 81
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 82
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 83
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 84
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 85
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 86
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 87
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 88
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 89
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 90
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 91
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 92
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 93
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 94
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 95
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 96
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 97
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 98
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 99
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 100
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 101
Products under Investigation by Universities/Institutes, H2 2012 (Contd..26) 102
Products under Investigation by Universities/Institutes, H2 2012 (Contd..27) 103
Products under Investigation by Universities/Institutes, H2 2012 (Contd..28) 104
Products under Investigation by Universities/Institutes, H2 2012 (Contd..29) 105
Products under Investigation by Universities/Institutes, H2 2012 (Contd..30) 106
Products under Investigation by Universities/Institutes, H2 2012 (Contd..31) 107
Products under Investigation by Universities/Institutes, H2 2012 (Contd..32) 108
Products under Investigation by Universities/Institutes, H2 2012 (Contd..33) 109
Products under Investigation by Universities/Institutes, H2 2012 (Contd..34) 111
Products under Investigation by Universities/Institutes, H2 2012 (Contd..35) 112
Products under Investigation by Universities/Institutes, H2 2012 (Contd..36) 113
Products under Investigation by Universities/Institutes, H2 2012 (Contd..37) 114
Products under Investigation by Universities/Institutes, H2 2012 (Contd..38) 115
Products under Investigation by Universities/Institutes, H2 2012 (Contd..39) 116
Products under Investigation by Universities/Institutes, H2 2012 (Contd..40) 117
Products under Investigation by Universities/Institutes, H2 2012 (Contd..41) 118
Products under Investigation by Universities/Institutes, H2 2012 (Contd..42) 119
Products under Investigation by Universities/Institutes, H2 2012 (Contd..43) 120
Products under Investigation by Universities/Institutes, H2 2012 (Contd..44) 121
Products under Investigation by Universities/Institutes, H2 2012 (Contd..45) 122
Products under Investigation by Universities/Institutes, H2 2012 (Contd..46) 123
Products under Investigation by Universities/Institutes, H2 2012 (Contd..47) 124
Products under Investigation by Universities/Institutes, H2 2012 (Contd..48) 125
Products under Investigation by Universities/Institutes, H2 2012 (Contd..49) 126
Products under Investigation by Universities/Institutes, H2 2012 (Contd..50) 127
Products under Investigation by Universities/Institutes, H2 2012 (Contd..51) 128
Products under Investigation by Universities/Institutes, H2 2012 (Contd..52) 129
Bristol-Myers Squibb Company, H2 2012 130
Johnson & Johnson, H2 2012 131
F. Hoffmann-La Roche Ltd., H2 2012 132
Kyowa Hakko Kirin Co., Ltd., H2 2012 133
Abbott Laboratories, H2 2012 134
Amgen Inc., H2 2012 135
Sanofi-Aventis, H2 2012 136
AstraZeneca PLC, H2 2012 137
Eli Lilly and Company, H2 2012 138
GlaxoSmithKline plc, H2 2012 139
Seattle Genetics, Inc., H2 2012 140
Tekmira Pharmaceuticals Corp., H2 2012 141
Genentech, Inc., H2 2012 142
Antigenics, Inc., H2 2012 143
MMR Information Systems, Inc., H2 2012 144
MedImmune LLC, H2 2012 145
Gilead Sciences, Inc., H2 2012 146
Daiichi Sankyo Company, Ltd, H2 2012 147
Merck & Co., Inc., H2 2012 148
Emergent BioSolutions Inc., H2 2012 149
Lentigen Corporation, H2 2012 150
Gamida Cell Ltd., H2 2012 151
Takeda Pharmaceutical Company Limited, H2 2012 152
Reliance Life Sciences Pvt. Ltd., H2 2012 153
Piramal Healthcare Limited, H2 2012 154
Celltrion, Inc., H2 2012 155
Bio-Path Holdings, Inc., H2 2012 156
ZIOPHARM Oncology, Inc., H2 2012 157
Millennium Pharmaceuticals, Inc., H2 2012 158
Novartis AG, H2 2012 159
Astellas Pharma Inc., H2 2012 160
Biocon Limited, H2 2012 161
BioMarin Pharmaceutical Inc., H2 2012 162
Cephalon, Inc., H2 2012 163
Chong Kun Dang Pharmaceutical, H2 2012 164
Eisai Co., Ltd., H2 2012 165
Glenmark Pharmaceuticals Ltd., H2 2012 166
OSI Pharmaceuticals, Inc., H2 2012 167
Pfizer Inc., H2 2012 168
SuperGen, Inc., H2 2012 169
Teva Pharmaceutical Industries Limited, H2 2012 170
Cell Therapeutics, Inc., H2 2012 171
Genmab A/S, H2 2012 172
Santaris Pharma A/S, H2 2012 173
Alfacell Corporation, H2 2012 174
Celgene Corporation, H2 2012 175
Onyx Pharmaceuticals, Inc., H2 2012 176
Bayer AG, H2 2012 177
Incyte Corporation, H2 2012 178
Merck KGaA, H2 2012 179
Access Pharmaceuticals, Inc., H2 2012 180
4SC AG, H2 2012 181
EpiCept Corporation, H2 2012 182
Celldex Therapeutics, Inc., H2 2012 183
AEterna Zentaris Inc., H2 2012 184
IMMUNOMEDICS, INC, H2 2012 185
Idera Pharmaceuticals, Inc., H2 2012 186
MethylGene Inc, H2 2012 187
Northwest Biotherapeutics, Inc., H2 2012 188
Cleveland BioLabs, Inc., H2 2012 189
Curis, Inc., H2 2012 190
Accentia Biopharmaceuticals, Inc., H2 2012 191
Allos Therapeutics, Inc, H2 2012 192
Portola Pharmaceuticals, Inc., H2 2012 193
Telik, Inc., H2 2012 194
TopoTarget A/S, H2 2012 195
Mundipharma International Limited, H2 2012 196
Pharmacyclics, Inc., H2 2012 197
Senesco Technologies, Inc., H2 2012 198
Progen Pharmaceuticals Limited, H2 2012 199
Green Cross Corporation, H2 2012 200
SymBio Pharmaceuticals Limited, H2 2012 201
Debiopharm Group, H2 2012 202
Chroma Therapeutics Ltd., H2 2012 203
Chipscreen Biosciences Ltd, H2 2012 204
Memgen, LLC., H2 2012 205
Aquinox Pharmaceuticals Inc., H2 2012 206
Aegera Therapeutics Inc., H2 2012 207
Ascenta Therapeutics, Inc., H2 2012 208
Cerulean Pharma, Inc., H2 2012 209
Provenance Biopharmaceuticals Corp., H2 2012 210
Arno Therapeutics, Inc., H2 2012 211
TetraLogic Pharmaceuticals, H2 2012 212
Celentyx Ltd., H2 2012 213
Fresenius Biotech GmbH, H2 2012 214
Semafore Pharmaceuticals, Inc., H2 2012 215
MSM Protein Technologies, Inc., H2 2012 216
Jennerex Biotherapeutics, Inc., H2 2012 217
Synageva BioPharma Corp., H2 2012 218
Cornerstone Pharmaceuticals, Inc., H2 2012 219
Omnitura Therapeutics Inc., H2 2012 220
Yaupon Therapeutics, Inc., H2 2012 221
Onconova Therapeutics, Inc, H2 2012 222
TcL Pharma SAS, H2 2012 223
Immune System Therapeutics Ltd., H2 2012 224
Intellikine, Inc., H2 2012 225
Myriad Pharmaceuticals, Inc., H2 2012 226
Morphogenesis, Inc., H2 2012 227
Mirna Therapeutics, Inc., H2 2012 228
Transtech Pharma, Inc., H2 2012 229
Xencor, Inc., H2 2012 230
iBio, Inc., H2 2012 231
Synthon Pharmaceuticals, Inc., H2 2012 232
PharmaMar, S.A., H2 2012 233
VentiRx Pharmaceuticals, Inc., H2 2012 234
Kinex Pharmaceuticals, LLC, H2 2012 235
CureTech Ltd., H2 2012 236
Cylene Pharmaceuticals, Inc., H2 2012 237
Nereus Pharmaceuticals, Inc., H2 2012 238
AVEO Pharmaceuticals, Inc., H2 2012 239
Lytix Biopharma AS, H2 2012 240
KAHR medical Ltd., H2 2012 241
Astellas Pharma GmbH, H2 2012 242
Dynamix Pharmaceuticals Ltd., H2 2012 243
Cancer Therapeutics CRC Pty Ltd, H2 2012 244
Zenyaku Kogyo Co., Ltd., H2 2012 245
LFB Biotechnologies, S.A.S.U., H2 2012 246
Mebiopharm Co., Ltd., H2 2012 247
Polaris Group, H2 2012 248
Probiomed S.A. de C.V., H2 2012 249
ImQuest Life Sciences, H2 2012 250
Shanghai CP Guojian Pharmaceutical Co.,Ltd., H2 2012 251
Immunovative Therapies, Ltd., H2 2012 252
PharmaTech International, Inc., H2 2012 253
Cell>Point, H2 2012 254
Advancell, H2 2012 255
Assessment by Monotherapy Products, H2 2012 256
Assessment by Combination Products, H2 2012 257
Assessment by Stage and Route of Administration, H2 2012 259
Assessment by Stage and Molecule Type, H2 2012 262
Lymphoma Therapeutics Drug Profile Updates 462
Lymphoma Therapeutics Discontinued Products 488
Lymphoma Therapeutics Discontinued Products (Contd..1) 489
Lymphoma Therapeutics Discontinued Products (Contd..2) 490
Lymphoma Therapeutics Discontinued Products (Contd..3) 491
Lymphoma Therapeutics Discontinued Products (Contd..4) 492
Lymphoma Therapeutics Discontinued Products (Contd..5) 493
Lymphoma Therapeutics Discontinued Products (Contd..6) 494
Lymphoma Therapeutics Discontinued Products (Contd..7) 495
Lymphoma Therapeutics Discontinued Products (Contd..8) 496
Lymphoma Therapeutics Discontinued Products (Contd..9) 497
Lymphoma Therapeutics Discontinued Products (Contd..10) 498
Lymphoma Therapeutics Discontinued Products (Contd..11) 499
Lymphoma Therapeutics Dormant Products 500
Lymphoma Therapeutics Dormant Products (Contd..1) 501
Lymphoma Therapeutics Dormant Products (Contd..2) 502
Lymphoma Therapeutics Dormant Products (Contd..3) 503
Lymphoma Therapeutics Dormant Products (Contd..4) 504
Lymphoma Therapeutics Dormant Products (Contd..5) 505
Lymphoma Therapeutics Dormant Products (Contd..6) 506
Lymphoma Therapeutics Dormant Products (Contd..7) 507
Lymphoma Therapeutics Dormant Products (Contd..8) 508
Lymphoma Therapeutics Dormant Products (Contd..9) 509
Lymphoma Therapeutics Dormant Products (Contd..10) 510
Lymphoma Therapeutics Dormant Products (Contd..11) 511
Lymphoma Therapeutics Dormant Products (Contd..12) 512
Lymphoma Therapeutics Dormant Products (Contd..13) 513
Lymphoma Therapeutics Dormant Products (Contd..14) 514
Lymphoma Therapeutics Dormant Products (Contd..15) 515
Lymphoma Therapeutics Dormant Products (Contd..16) 516
Lymphoma Therapeutics Dormant Products (Contd..17) 517
Lymphoma Therapeutics Dormant Products (Contd..18) 518
Lymphoma Therapeutics Dormant Products (Contd..19) 519
Lymphoma Therapeutics Dormant Products (Contd..20) 520
Lymphoma Therapeutics Dormant Products (Contd..21) 521
Lymphoma Therapeutics Dormant Products (Contd..22) 522
Lymphoma Therapeutics Dormant Products (Contd..23) 523
Lymphoma Therapeutics Dormant Products (Contd..24) 524
Lymphoma Therapeutics Dormant Products (Contd..25) 525
Lymphoma Therapeutics Dormant Products (Contd..26) 526
Lymphoma Therapeutics Dormant Products (Contd..27) 527
Lymphoma Therapeutics Dormant Products (Contd..28) 528
Lymphoma Therapeutics Dormant Products (Contd..29) 529
Lymphoma Therapeutics Dormant Products (Contd..30) 530
Lymphoma Therapeutics Dormant Products (Contd..31) 531
Lymphoma Therapeutics Dormant Products (Contd..32) 532
Lymphoma Therapeutics Dormant Products (Contd..33) 533
Lymphoma Therapeutics Dormant Products (Contd..34) 534
Lymphoma Therapeutics Dormant Products (Contd..35) 535
Lymphoma Therapeutics Dormant Products (Contd..36) 536
Lymphoma Therapeutics Dormant Products (Contd..37) 537
Lymphoma Therapeutics Dormant Products (Contd..38) 538
Lymphoma Therapeutics Dormant Products (Contd..39) 539
Lymphoma Therapeutics Dormant Products (Contd..40) 540
Lymphoma Therapeutics Dormant Products (Contd..41) 541
Lymphoma Therapeutics Dormant Products (Contd..42) 542
Lymphoma Therapeutics Dormant Products (Contd..43) 543
Lymphoma Therapeutics Dormant Products (Contd..44) 544

List of Chart


Number of Products under Development for Lymphoma, H2 2012 26
Products under Development for Lymphoma - Comparative Analysis, H2 2012 27
Products under Development by Companies, H2 2012 28
Products under Investigation by Universities/Institutes, H2 2012 39
Late Stage Products, H2 2012 56
Mid Clinical Stage Products, H2 2012 57
Early Clinical Stage Products, H2 2012 58
Discovery and Pre-Clinical Stage Products, H2 2012 59
Assessment by Monotherapy Products, H2 2012 256
Assessment by Combination Products, H2 2012 257
Assessment by Route of Administration, H2 2012 258
Assessment by Stage and Route of Administration, H2 2012 259
Assessment by Molecule Type, H2 2012 260
Assessment by Stage and Molecule Type, H2 2012 261

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2500
$ 5000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top